
Tema Oncology ETF
CANCNASDAQTemaEquity
As of Nov 16, 2026 close
- Assets (AUM)
- $206.87M
- Expense ratio
- 0.75%
- Dividend yield
- 0.05%
- Holdings
- 58
- 52-week range
- $33.25$47.00
- Volume (live)
- -
- Avg. volume (3M)
- 18.71K
CANC ETF Holdings: Tema Oncology ETF
The largest positions with their portfolio weights, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 25 of 58 CANC Holdings by Portfolio Weight
Holdings data last updated Nov 14, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 25 positions.
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | ![]() | Genmab A/S | Stock | 5.92% |
| 2 | ![]() | Revolution Medicines, Inc. | Stock | 5.43% |
| 3 | ![]() | Eli Lilly and Company | Stock | 5.43% |
| 4 | ![]() | Merck & Co., Inc. | Stock | 4.86% |
| 5 | ![]() | Cogent Biosciences, Inc. | Stock | 4.30% |
| 6 | ![]() | BeOne Medicines AG | Stock | 4.24% |
| 7 | SWX:NOVN | Novartis AG | Stock | 4.06% |
| 8 | ![]() | AbbVie Inc. | Stock | 3.76% |
| 9 | ![]() | Exelixis, Inc. | Stock | 3.72% |
| 10 | ![]() | BridgeBio Pharma, Inc. | Stock | 3.16% |
| 11 | OTC:RHHBY | Roche Holding AG | Stock | 3.13% |
| 12 | ![]() | Halozyme Therapeutics, Inc. | Stock | 2.97% |
| 13 | ![]() | Enliven Therapeutics, Inc. | Stock | 2.81% |
| 14 | ![]() | CG Oncology, Inc. | Stock | 2.73% |
| 15 | ![]() | Bristol-Myers Squibb Company | Stock | 2.68% |
| 16 | ![]() | Relay Therapeutics, Inc. | Stock | 2.37% |
| 17 | LON:AZN | AstraZeneca PLC | Stock | 2.33% |
| 18 | ![]() | Johnson & Johnson | Stock | 2.30% |
| 19 | ![]() | IDEAYA Biosciences, Inc. | Stock | 2.26% |
| 20 | ![]() | Erasca, Inc. | Stock | 2.15% |
| 21 | ![]() | Immunome, Inc. | Stock | 2.12% |
| 22 | ![]() | Amgen Inc. | Stock | 1.96% |
| 23 | ![]() | Zai Lab Limited | Stock | 1.92% |
| 24 | ![]() | Legend Biotech Corporation | Stock | 1.88% |
| 25 | ![]() | Iovance Biotherapeutics, Inc. | Stock | 1.74% |
Source: Fund holdings disclosures. Last updated Nov 14, 2026. Data sources and methodology
Frequently Asked Questions About Tema Oncology ETF Holdings
What are the top holdings in CANC?
In holdings data last updated Nov 14, 2026, CANC's largest holdings are Genmab A/S (GMAB) at 5.92%, Revolution Medicines, Inc. (RVMD) at 5.43%, Eli Lilly and Company (LLY) at 5.43%, Merck & Co., Inc. (MRK) at 4.86% and Cogent Biosciences, Inc. (COGT) at 4.30%. Together these 5 positions make up 25.9% of the fund. CANC holds 58 securities in all; the holdings data lists the top 25 by weight.
How concentrated is CANC's portfolio?
In holdings data last updated Nov 14, 2026, the 10 largest of CANC's 58 positions make up 44.9% of assets. The largest single position is Genmab A/S (GMAB) at 5.92%. The top 25 listed positions add up to 80.2%, so the remaining 33 holdings share 19.8%. Its largest sector, Healthcare, is 100.0% of the portfolio.
What is CANC's sector allocation?
In holdings data last updated Nov 14, 2026, CANC's largest sector weights are Healthcare (100.0%), together 100.0% of the portfolio. It has exposure to 1 sector in total.
What countries does CANC invest in?
In holdings data last updated Nov 14, 2026, 76.6% of CANC's portfolio is invested in the United States, followed by Switzerland (11.4%), Denmark (5.9%) and the United Kingdom (3.2%). CANC has exposure to 7 countries in total. By asset type the fund is 98.9% stocks and 1.1% cash.





















